202 related articles for article (PubMed ID: 24864437)
1. [Follow-up study on patients with vernal keratoconjunctivitis undergoing topical 0.1% tacrolimus treatment].
Harada N; Inada N; Ishimori A; Shoji J; Sawa M
Nippon Ganka Gakkai Zasshi; 2014 Apr; 118(4):378-84. PubMed ID: 24864437
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Clinical Efficacy and Safety of Prolonged Treatment of Vernal and Atopic Keratoconjunctivitis Using Topical Tacrolimus.
Hirota A; Shoji J; Inada N; Shiraki Y; Yamagami S
Cornea; 2022 Jan; 41(1):23-30. PubMed ID: 34870621
[TBL] [Abstract][Full Text] [Related]
3. [Allergy related factors in tears of patients with vernal keratoconjunctivitis undergoing topical 0.1% tacrolimus treatment].
Hori S; Shoji J; Inada N; Sawa M
Nippon Ganka Gakkai Zasshi; 2011 Dec; 115(12):1079-85. PubMed ID: 22312812
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis.
Wan Q; Tang J; Han Y; Wang D; Ye H
Ophthalmic Res; 2018; 59(3):126-134. PubMed ID: 28803239
[TBL] [Abstract][Full Text] [Related]
5. Topical Tacrolimus for Chronic Allergic Conjunctival Disease with and without Atopic Dermatitis.
Shoji J; Ohashi Y; Fukushima A; Miyazaki D; Uchio E; Takamura E; Fujishima H; Namba K; Kumagai N; Ebihara N; Okamoto S
Curr Eye Res; 2019 Jul; 44(7):796-805. PubMed ID: 30947551
[No Abstract] [Full Text] [Related]
6. Tailored approach to the treatment of vernal keratoconjunctivitis.
Sacchetti M; Lambiase A; Mantelli F; Deligianni V; Leonardi A; Bonini S
Ophthalmology; 2010 Jul; 117(7):1294-9. PubMed ID: 20382430
[TBL] [Abstract][Full Text] [Related]
7. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis.
Ebihara N; Ohashi Y; Uchio E; Okamoto S; Kumagai N; Shoji J; Takamura E; Nakagawa Y; Nanba K; Fukushima A; Fujishima H
J Ocul Pharmacol Ther; 2009 Aug; 25(4):365-72. PubMed ID: 19441889
[TBL] [Abstract][Full Text] [Related]
8. Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis.
Wakamatsu TH; Tanaka M; Satake Y; Dogru M; Fukagawa K; Igarashi A; Fujishima H
Mol Vis; 2011 Apr; 17():932-8. PubMed ID: 21541276
[TBL] [Abstract][Full Text] [Related]
9. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children.
Labcharoenwongs P; Jirapongsananuruk O; Visitsunthorn N; Kosrirukvongs P; Saengin P; Vichyanond P
Asian Pac J Allergy Immunol; 2012 Sep; 30(3):177-84. PubMed ID: 23156846
[TBL] [Abstract][Full Text] [Related]
10. Topical tacrolimus 0.03% as sole therapy in vernal keratoconjunctivitis: a randomized double-masked study.
Müller GG; José NK; de Castro RS
Eye Contact Lens; 2014 Mar; 40(2):79-83. PubMed ID: 24418865
[TBL] [Abstract][Full Text] [Related]
11. Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes.
Vichyanond P; Pacharn P; Pleyer U; Leonardi A
Pediatr Allergy Immunol; 2014 Jun; 25(4):314-22. PubMed ID: 24438133
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of a new therapy using rebamipide eyedrops in patients with VKC/AKC refractory to conventional anti-allergic treatments.
Ueta M; Sotozono C; Koga A; Yokoi N; Kinoshita S
Allergol Int; 2014 Mar; 63(1):75-81. PubMed ID: 24457813
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Safety and Efficacy of Tacrolimus 0.1% in Severe Pediatric Vernal Keratoconjunctivitis.
Caputo R; Marziali E; de Libero C; Di Grande L; Danti G; Virgili G; Villani E; Mori F; Bacci GM; Lucenteforte E; Pucci N
Cornea; 2021 Nov; 40(11):1395-1401. PubMed ID: 34029239
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.
Pucci N; Novembre E; Cianferoni A; Lombardi E; Bernardini R; Caputo R; Campa L; Vierucci A
Ann Allergy Asthma Immunol; 2002 Sep; 89(3):298-303. PubMed ID: 12269651
[TBL] [Abstract][Full Text] [Related]
15. Topical bromfenac sodium for long-term management of vernal keratoconjunctivitis.
Uchio E; Itoh Y; Kadonosono K
Ophthalmologica; 2007; 221(3):153-8. PubMed ID: 17440276
[TBL] [Abstract][Full Text] [Related]
16. Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis.
Akman A; Irkeç M; Orhan M
Eye (Lond); 1998; 12 ( Pt 2)():291-5. PubMed ID: 9683957
[TBL] [Abstract][Full Text] [Related]
17. Role of ocular cytology in vernal keratoconjunctivitis.
Bruschi G; Ghiglioni DG; Osnaghi S; Rosazza C; Pires Marafon D; Landi M; Marchisio PG
Immun Inflamm Dis; 2020 Mar; 8(1):3-7. PubMed ID: 31804769
[TBL] [Abstract][Full Text] [Related]
18. Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis.
Chatterjee S; Agrawal D
Cornea; 2016 Nov; 35(11):1444-1448. PubMed ID: 27310883
[TBL] [Abstract][Full Text] [Related]
19. Vernal keratoconjunctivitis in Thailand.
Kosrirukvongs P; Vichyanond P; Wongsawad W
Asian Pac J Allergy Immunol; 2003 Mar; 21(1):25-30. PubMed ID: 12931748
[TBL] [Abstract][Full Text] [Related]
20. Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis.
Kheirkhah A; Zavareh MK; Farzbod F; Mahbod M; Behrouz MJ
Eye (Lond); 2011 Jul; 25(7):872-80. PubMed ID: 21475312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
